8DPL image
Deposition Date 2022-07-15
Release Date 2023-07-19
Last Version Date 2025-05-14
Entry Detail
PDB ID:
8DPL
Keywords:
VIRAL PROTEIN/Immune System
Title:
Structure of EBOV GP lacking the mucin-like domain with 2.1.1D5 scFv and 6D6 scFv bound
Biological Source:
Source Organism:
Homo sapiens (Taxon ID: 9606)
Mus musculus (Taxon ID: 10090)
Ebola virus - Mayinga, Zaire, 1976 (Taxon ID: 128952)
Host Organism:
Drosophila melanogaster
Method Details:
Experimental Method:
ELECTRON MICROSCOPY
Resolution:
2.53 Å
Aggregation State:
PARTICLE
Reconstruction Method:
SINGLE PARTICLE
8DPL validation report
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:2.1.1D5 heavy chain variable domain
Chain IDs:A (auth: F), D (auth: A), G (auth: K)
Chain Length:120
Number of Molecules:3
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:2.1.1D5 light chain variable domain
Chain IDs:B (auth: G), E (auth: B), H (auth: L)
Chain Length:112
Number of Molecules:3
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:6D6 single-chain variable fragment
Chain IDs:C (auth: H), F (auth: C), I (auth: O)
Chain Length:243
Number of Molecules:3
Biological Source:Mus musculus
Protein Blast
Polymer Type:polypeptide(L)
Molecule:Glycoprotein GP1
Gene (Uniprot):GP
Chain IDs:J (auth: I), L (auth: D), N (auth: M)
Chain Length:280
Number of Molecules:3
Biological Source:Ebola virus - Mayinga, Zaire, 1976
UniProt ID:Q05320 Pfam ID:PF01611, PF22307
Protein Blast
Polymer Type:polypeptide(L)
Molecule:Glycoprotein GP2
Chain IDs:K (auth: J), M (auth: E), O (auth: N)
Chain Length:136
Number of Molecules:3
Biological Source:Ebola virus - Mayinga, Zaire, 1976
UniProt ID:Q05320 Pfam ID:PF01611, PF22307
Ligand Molecules
NAG
Primary Citation
The evolution and determinants of neutralization of potent head-binding antibodies against Ebola virus.
Cell Rep 42 113366 113366 (2023)
PMID: 37938974 DOI: 10.1016/j.celrep.2023.113366

Abstact

Monoclonal antibodies against the Ebola virus (EBOV) surface glycoprotein are effective treatments for EBOV disease. Antibodies targeting the EBOV glycoprotein (GP) head epitope have potent neutralization and Fc effector function activity and thus are of high interest as therapeutics and for vaccine design. Here we focus on the head-binding antibodies 1A2 and 1D5, which have been identified previously in a longitudinal study of survivors of EBOV infection. 1A2 and 1D5 have the same heavy- and light-chain germlines despite being isolated from different individuals and at different time points after recovery from infection. Cryoelectron microscopy analysis of each antibody in complex with the EBOV surface GP reveals key amino acid substitutions in 1A2 that contribute to greater affinity, improved neutralization potency, and enhanced breadth as well as two strategies for antibody evolution from a common site.

Legend

Protein

Chemical

Disease

Primary Citation of related structures
8DPL